Accessibility Menu
CorMedix logo

CorMedix(NASDAQ) CRMD

Market Cap$576.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-51%
5 Year+23%
1 Year-39%
1 Month-6%
$7.18
-2.38%
-0.18Today
CorMedix last closing stock price
MetricPriceDate
Last closeUSD 7.352026-07-28
CorMedix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.26%USD 8.192026-07-21
1 month-6.37%USD 7.852026-06-26
3 month-1.74%USD 7.482026-04-29
Year to date-36.8%USD 11.632025-12-31
1 year-38.65%USD 11.982025-07-28
3 year+64.8%USD 4.462023-07-28
5 year+23.12%USD 5.972021-07-29
Since inception-51%USD 15.002010-05-13

CorMedix Financials at a Glance

Market Cap

$576.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$400.05M

Net Income (TTM)

$181.01M

EPS (TTM)

$2.10

P/E Ratio

3.50

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$7.18

Volume

1,362,415

Open

$7.36

Previous Close

$7.19

Daily Range

$7.13 - $7.43

52-Week Range

$6.13 - $14.96

Estimated Earnings Date

Aug 6, 2026

CRMD News

cellectis

Why Shares of CorMedix Are Slumping Thursday

James HalleyJun 29, 2023
Person in a lab looking through a microscope

Why CorMedix Stock Was Plummeting on Tuesday

Eric VolkmanAug 9, 2022
Delay note pinned to board

Why CorMedix Stock Is Getting Crushed Today

Keith SpeightsSep 7, 2021
FDA Not Approved stamp

Why CorMedix Stock Is Crashing Today

Keith SpeightsMar 1, 2021
businessman stock down

Here's Why CorMedix Dropped as Much as 27.1% Today

Maxx ChatskoFeb 14, 2019

CRMD: Motley Fool Moneyball Superscore

65

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CorMedix

CorMedix helps prevent serious infections for people needing regular blood treatments. Its main product, DefenCath, protects patients with catheters from dangerous bacteria. This solution is used in hospitals and clinics to keep patients safer during dialysis.

Products and Services

  • DefenCath: Antimicrobial solution for preventing bloodstream infections in dialysis patients using central venous catheters. All product sales come from DefenCath.
  • Drug Product Segment: All sales come from DefenCath, targeting U.S. hospitals and outpatient dialysis centers.
  • Future Portfolio: Pending acquisition of Melinta Therapeutics will add new anti-infective drugs.

Growth and Expansion

  • Launched DefenCath in U.S. hospitals (April 2024) and outpatient clinics (July 2024).
  • Secured multi-year supply deals with major U.S. dialysis providers in 2024.
  • Announced acquisition of Melinta Therapeutics in August 2025 to expand product offerings.
  • Gained Medicare reimbursement approvals (NTAP, TDAPA, pass-through) between 2024 and 2025.

What Makes CorMedix Stand Out

CorMedix is the only company with an FDA-approved antimicrobial catheter lock solution in the U.S. It holds exclusive rights for DefenCath until 2028, with extended protection through 2033. Strategic supply agreements cover about 60% of U.S. outpatient dialysis centers.

Five Things You Need to Know

  • Revenue was $40 million in Q2 2025, up 4,829% from Q2 2024.
  • Gross profit reached $38 million in Q2 2025, up 12,683% year-over-year.
  • Net income was $20 million in Q2 2025, reversing a $14 million loss in Q2 2024.
  • Cash and short-term investments totaled $191 million as of June 30, 2025.

Bottom Line

CorMedix transformed from a single-product company to a profitable business in one year. Its focus on infection prevention and strategic expansion shapes its current market position.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

191

CEO

Joseph Todisco, MBA

Website

www.cormedix.com

Headquarters

Parsippany, NJ 07054, US

CRMD Financials

Key Financial Metrics (TTM)

Gross Margin

85.83%

Operating Margin

48.41%

Net Income Margin

45.25%

Return on Equity

50.38%

Return on Capital

27.09%

Return on Assets

22.19%

Earnings Yield

28.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$576.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

78.45M

Volume

1.36M

Avg. Volume

1.30M

Financials (TTM)

Gross Profit

$343.39M

Operating Income

$193.67M

EBITDA

$212.72M

Operating Cash Flow

$197.69M

Capital Expenditure

-$1.30M

Free Cash Flow

$196.39M

Cash & ST Invst.

$178.09M

Total Debt

$147.42M

CorMedix Performance Analysis

CorMedix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 65,408-65.7%
20232023-12-31USD 0N/A
20242024-12-31USD 43,472,170N/A
20252025-12-31USD 311,709,000617.0%
CorMedix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301.7%
Q32025-09-30162.4%
Q42025-12-3123.3%
Q12026-03-31-0.9%
CorMedix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.74-1.5%
20232023-12-31USD -0.9123.4%
20242024-12-31USD -0.30-66.5%
20252025-12-31USD 2.03N/A
CorMedix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-6.7%
Q32025-09-30350.0%
Q42025-12-31-88.1%
Q12026-03-31180.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$127.43M

+226.1%

Gross Profit

$105.12M

+180.4%

Gross Margin

82.50%

N/A

Market Cap

$576.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.02M

N/A

Employees

191

N/A

Net Income

$38.60M

+87.0%

EBITDA

$66.19M

+218.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$178.09M

+129.8%

Total Debt

$147.42M

+30831.4%

Accounts Receivable

$154.81M

+183.5%

Inventory

$30.73M

+310.4%

Long Term Debt

$147.42M

+48377.1%

Short Term Debt

$0.00

-100.0%

Return on Assets

22.19%

N/A

Return on Invested Capital

28.20%

N/A

Free Cash Flow

$41.65M

+111.2%

Operating Cash Flow

$42.38M

+114.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PROKProKidney Corp.
$1.54+0.00%
KURAKura Oncology, Inc.
$8.93-4.08%
ABUSArbutus Biopharma Corp
$4.29-2.72%
EYPTEyePoint Pharmaceuticals, Inc.
$11.92-0.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Questions About CRMD

What is the current price of CorMedix?

CorMedix is trading at $7.19 per share.

What is the 52-week range for CorMedix?

Over the past 52 weeks, CorMedix has traded between $6.13 and $14.96.

How much debt does CorMedix have?

As of the most recent reporting period, CorMedix reported total debt of $144.89M.

How much cash does CorMedix have on hand?

CorMedix reported $178.74M in cash and cash equivalents in its most recent financial results.

What is CorMedix’s dividend yield?

CorMedix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services